None of the ATM, ATR, Chk1 and Chk2 polymorphisms was found to significantly affect OS nor PFS in ourcohort of advanced stage ovarian cancer patients treated with adjuvant chemotherapy, while genotype G/G of CDK12 polymorphism (rs1054488) predicted worse OS and PFS than the genotype A/A-A/G in univariate analysis. This evidence concerns the gene CHEK2 and ovarian carcinoma.